Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Wall Street Today | Monday Market Climbs, But Not Past Last Weeks Fall
Why Is Moderna Stock Trading Higher On Monday?
Moovin Stonks | Market on the Rise, Meme Stocks Climbing
Palantir Stock Soars After S&P 500 Inclusion, AI Deal With BP Fuels Additional Gains – What's Next?
Palantir Technologies, Dell Technologies, And S&P MidCap 400 Constituent Erie Indemnity Co. Set To Join S&P 500; Will Replace American Airlines Group, Etsy And Bio-Rad Laboratories
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
QuidelOrtho Analyst Ratings
'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio
Reported Earlier, Vaxcyte Prices $1.3B Public Offering Of 10,194,175 Common Shares And Pre-Funded Warrants At $103/Share
Vaxcyte Analyst Ratings
Market Mover | Vaxcyte Shares Surge 36% After Positive Topline Data from 1/2 Study of VAX-31 Vaccine
Vaxcyte Announced Topline Results From Phase 1/2 Study Of VAX-31, The Company's 31-valent Pneumococcal Conjugate Vaccine Candidate; At All Doses, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses For All 31 Serotypes
12 Health Care Stocks Moving In Monday's Pre-Market Session
Market Whales and Their Recent Bets on ALNY Options
Alnylam Tumbles, BridgeBio Gains After Heart Drug Data
Alnylam Says Typo In Presentation Misstated Heart Drug Benefit